Prasugrel, like Clopidogrel, is a thienopyridine and a prodrug which inhibits ADP receptors by irreversibly acting on the P2Y12 receptor on platelets. Since platelets participate in the initiation and/or evolution of thrombotic complications of atherosclerotic disease, inhibition of platelet function can result in the reduction of the rate of death and the rate of ischaemic cardiovascular events such as myocardial infarction or stroke.
Prasugrel is a prodrug, oxidation of which by intestinal and hepatic cytochrome P-450 enzymes convert it into its active metabolite. The active metabolite of prasugrel prevents binding of adenosine diphosphate (ADP) to its platelet receptor, impairing the ADP-mediated activation of the glycoprotein GPIIb/IIIa complex.
Prasugrel has a rapid and almost complete absorption after oral ingestion of a loading dose. Furthermore, it has a greater antiplatelet effect than clopidogrel because it is metabolized more efficiently. Some of the differences in metabolism between clopidogrel and prasugrel may be explained by genetic polymorphisms affecting the cytochrome P-450 system.
Storage conditions: Store between 2- 8o C
Packaging: polyethylene nylon plastic bag